The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.
About Covishield:
The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.
About Covaxin:
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Important takeaways for all competitive exams:
In the vast cosmos, galaxies come in various shapes and sizes, but few captivate astronomers…
In a major stride toward developing hypersonic weapons, the Defence Research and Development Laboratory (DRDL),…
In an era where globalization seeks to bring countries closer through trade, Free Trade Agreements…
India and France are poised to officially conclude a ₹63,000-crore government-to-government (G-to-G) deal on April…
In a major development for Indian higher education and the arts, the Film and Television…
Similipal, a unique and ecologically rich region in Odisha, has officially been accorded national park…
![](data:image/svg+xml;charset=utf-8,<svg height="206px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="245px" width="245px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
